Tower Research Capital (TRC)’s Transphorm, Inc. Common Stock TGAN Stock Holding History

Tower Research Capital (TRC)’s Portfolio TGAN Stock Details TGAN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,217	Closed	-$15.8K	–	6114
2024 Q1	$15.8K	Buy	3,217 +689	+27%	+$3.27K	﹤0.01%	3222
2023 Q4	$9.23K	Sell	2,528 -2,403	-49%	-$6.58K	﹤0.01%	4420
2023 Q3	$10.9K	Buy	4,931 +2,626	+114%	+$7.33K	﹤0.01%	4056
2023 Q2	$7.84K	Sell	2,305 -781	-25%	-$2.82K	﹤0.01%	4520
2023 Q1	$12K	Buy	3,086 +1,319	+75%	+$5.81K	﹤0.01%	4151
2022 Q4	$10K	Sell	1,767 -998	-36%	-$5.87K	﹤0.01%	4109
2022 Q3	$14K	Buy	2,765 +275	+11%	+$1.35K	﹤0.01%	4235
2022 Q2	$9K	Buy	+2,490	New	+$15.9K	﹤0.01%	4610

Tower Research Capital (TRC)'s TGAN Position: Q2 2024 in Review

Tower Research Capital (TRC) sold out of Transphorm, Inc. Common Stock (TGAN) in Q2 2024, closing a stake of 3,217 shares — an estimated $15.8K sold.

Tower Research Capital (TRC) first reported a position in TGAN in Q2 2022 and held it in 8 quarters. The position peaked at $15.8K in Q1 2024. 0 funds tracked by Wall St. Rank hold TGAN as of Q2 2024.

Tower Research Capital (TRC) reported no remaining Transphorm, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Tower Research Capital (TRC) sold 3,217 Transphorm, Inc. Common Stock shares in Q2 2024, an estimated $15.8K.
Tower Research Capital (TRC) first reported a position in Transphorm, Inc. Common Stock in Q2 2022 and held it in 8 quarters.
Tower Research Capital (TRC)'s Transphorm, Inc. Common Stock position peaked at $15.8K in Q1 2024.
0 funds tracked by Wall St. Rank held Transphorm, Inc. Common Stock as of Q2 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2024, filed 13 Aug 2024.